The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1539
A Two-Dose Hepatitis B Vaccine for Adults (Heplisav-B)
The full article is available to subscribers Subscriber Login   

The FDA has approved a two-dose hepatitis B virus (HBV) vaccine (Heplisav-B – Dynavax) for use in adults ≥18 years old. The three other HBV vaccines marketed in the US are usually administered in 3 doses. Engerix-B and Recombivax HB are licensed for use in persons of all ages. A combination hepatitis A/B vaccine (Twinrix) contains the same hepatitis B component as Engerix-B and is licensed for use only in adults.1

HEPATITIS B VIRUS INFECTION — HBV infection is transmitted through percutaneous or mucosal contact with infectious blood or other bodily fluids. Risk factors for acquisition in adults include occupational exposure, IV drug abuse, unprotected sex, and hemodialysis. Chronic HBV infection can cause cirrhosis and hepatic cancer. Universal childhood vaccination against HBV, introduced in the US in 1991, has significantly ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Two-Dose Hepatitis B Vaccine for Adults (Heplisav-B)
Article code: 1539a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian